Anaphylaxis
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Medicine information GOBIVAZ 50mg solution for injection in pre-filled pen
- Product code:
- W72146001
- Quantity:
- 1
- Indicated for:
- autoimmune inflammatory diseases
- Route of administration:
- injectable
- Substance:
- golimumab (monoclonal antibody)
- ATC
- L04AB06 — Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Tumor necrosis factor alpha (tnf-alpha) inhibitors
Golimumab is a biologic medicine used for inflammatory autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and ulcerative colitis. It is used when inflammation causes pain, stiffness, joint damage risk or persistent bowel symptoms.
Golimumab blocks tumour necrosis factor alpha, a protein involved in the inflammatory process. By reducing this signal, it may lessen pain, swelling, stiffness and disease activity. The effect may take time, so the doctor will reassess whether the treatment is working well enough. It may be combined with methotrexate or other medicines according to the treatment plan.
The medicine is given as a subcutaneous injection, usually monthly, or intravenously in certain situations, depending on the prescribed formulation. Before starting, patients need screening for tuberculosis, hepatitis B and other relevant infections. Do not receive live vaccines unless your doctor agrees. Report fever, repeated infections, persistent cough, non-healing wounds or planned surgery.
Common side effects include upper respiratory tract infections, sore throat, blocked or runny nose and injection-site reactions. Serious but less common problems include severe infections, reactivation of tuberculosis or hepatitis B, allergic reactions, worsening heart failure, neurological disorders or certain cancers. Seek prompt help for high fever, breathing difficulty, jaundice or sudden weakness.
Golimumab blocks tumour necrosis factor alpha, a protein involved in the inflammatory process. By reducing this signal, it may lessen pain, swelling, stiffness and disease activity. The effect may take time, so the doctor will reassess whether the treatment is working well enough. It may be combined with methotrexate or other medicines according to the treatment plan.
The medicine is given as a subcutaneous injection, usually monthly, or intravenously in certain situations, depending on the prescribed formulation. Before starting, patients need screening for tuberculosis, hepatitis B and other relevant infections. Do not receive live vaccines unless your doctor agrees. Report fever, repeated infections, persistent cough, non-healing wounds or planned surgery.
Common side effects include upper respiratory tract infections, sore throat, blocked or runny nose and injection-site reactions. Serious but less common problems include severe infections, reactivation of tuberculosis or hepatitis B, allergic reactions, worsening heart failure, neurological disorders or certain cancers. Seek prompt help for high fever, breathing difficulty, jaundice or sudden weakness.
General data about GOBIVAZ 50mg
- Substance:
- golimumab
- Date of latest medicines list:
- 01-09-2026
- Product code:
- W72146001
- Strength:
- 50mg
- Pharmaceutical form:
- solution for injection in pre-filled pen
- Quantity:
- 1
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for golimumab
Official documents
The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.
The correspondence between the document and the displayed text is unconfirmed.
- Source institution
- EMA
- Document language
- English
- Source record: first published
- 20/11/2025
- Source record: last updated
- 21/07/2026
Warnings:
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.